Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|HER2 Positive
Interventions: DRUG: PTC+Pertuzumab|DRUG: FEC-T+Pertuzumab
Sponsor: The Netherlands Cancer Institute
Collaborators: Roche Pharma AG|Borstkanker Onderzoek Groep